Leadership

Larry Edwards

Chief Executive Officer

Maria Stahl

Chief Business Officer

Christopher Watt

Senior Vice President, Finance

Larry Edwards

Chief Executive Officer

Larry Edwards has served as Chief Executive Officer since August 2019.  Mr. Edwards joined Tetraphase in July 2015 as Vice President of Marketing and became Vice President of Commercial Operations in January 2016. Mr. Edwards then worked as Chief Commercial Officer from January 2017 to February 2018 until he most recently served as Chief Operating Officer from March 2018 until July 2019. Prior to joining Tetraphase, Mr. Edwards served as Senior Director of Marketing, Gram-negative Franchise, with Cubist Pharmaceuticals, Inc., from April 2014 to July 2015 (Cubist acquired by Merck & Co., Inc.). From 2010 to 2014, he served as Global Marketing Director, Clostridium difficile and New Infectious Disease Products, with Merck & Co., Inc., where he also served as Associate Director of Vaccines and Infectious Diseases from 2007 to 2010, and held various management training and sales positions of increasing responsibility from 1999 to 2007. Mr. Edwards received a B.S. in business and healthcare administration from Ohio University.

Maria Stahl

Chief Business Officer

Maria Stahl has served as Chief Business Officer since July 2019. Ms. Stahl joined Tetraphase in March 2015 as Senior Vice President and General Counsel. Prior to joining Tetraphase, Ms. Stahl served as Senior Vice President, General Counsel, and Secretary of Idenix Pharmaceuticals, Inc. from October 2010 to August 2014. Ms. Stahl previously served at Idenix as Vice President, Associate General Counsel from February 2008 to November 2009, and as Assistant General Counsel from February 2007 to February 2008. Prior to rejoining Idenix, Ms. Stahl served as General Counsel of Zipcar, Inc., from November 2009 to October 2010. From February 2005 to February 2007, she served as Vice President, Corporate Counsel of Capital Crossing Bank. Prior to that, Ms. Stahl was at Wilmer Cutler Pickering Hale and Dorr LLP from 1997 to 2005. She received a B.A. from Providence College and a J.D. from Yale Law School.

Christopher Watt

Senior Vice President, Finance

Christopher Watt has served as our Senior Vice President of Finance since January 2017, previously serving as Vice President of Finance upon joining Tetraphase in July 2015. Prior to joining the company, Mr. Watt spent 10 years at Biogen, Inc., most recently as Senior Director, Global Commercial Finance. From 2009 to 2010, Mr. Watt served as the Finance Director of Biogen for the UK and Ireland affiliates, and from 2006 to 2009 as Director of Business Planning, International, based in Switzerland. Prior to Biogen, Mr. Watt spent four years in various financial planning and analysis roles at InterSystems Corporation. Mr. Watt holds a B.A. from Colby College and an M.B.A. from the University of Michigan.

Board of Directors

L. Patrick Gage, Ph.D.

Chairman

Leonard Patrick Gage, Ph.D. has served as a member of our board of directors and as Chairman of our board of directors since December…

Garen Bohlin

Garen Bohlin has served as a member of our board of directors since July 2010. Since May 2012, Mr. Bohlin has served on the…

Jeffrey A. Chodakewitz, M.D.

Jeffrey A. Chodakewitz, M.D. has served as a member of our board of directors since June 2014. Dr. Chodakewitz currently serves as a…

John G. Freund, M.D.

John Freund, M.D. has served as a member of our board of directors since October 2012. Dr. Freund founded Skyline Ventures, a venture capital…

Gerri Henwood

Gerri Henwood has served as a member of our board of directors since April 2015. Since 2008, Ms. Henwood has served as President…

Guy Macdonald

Guy Macdonald has served as a member of our board of directors since January 2008, in addition to serving as our President and…

Nancy J. Wysenski

Nancy Wysenski has served as a member our board of directors since March 2014. From December 2009 through June 2012, Ms. Wysenski served as…

L. Patrick Gage, Ph.D.

Chairman

Leonard Patrick Gage, Ph.D. has served as a member of our board of directors and as Chairman of our board of directors since December 2011. Since July 2002, Dr. Gage has served as a consultant to the biopharmaceutical industry. From 1998 to 2002, Dr. Gage served as President of Wyeth Research (now part of Pfizer, Inc.). Prior to joining Wyeth Research, he served in various positions at Genetics Institute, Inc., a publicly traded biotechnology company, from 1989 to 1998, first as head of Research and Development, then as Chief Operating Officer and eventually as President. From 1971 to 1989, Dr. Gage served in various positions in research management with Hoffmann-La Roche Inc., a pharmaceutical company, most recently serving as Vice President responsible for U.S. drug discovery. Dr. Gage has served on the board of directors of Cytokinetics, Incorporated, a publicly traded biopharmaceuticals company, since November 2009 and as Chairman of its board of directors since March 2010. Previously he served on the board of directors of PDL BioPharma, Inc., a publicly traded biotechnology company, from 2003 through 2008, as the Chairman of its board of directors in 2007, and as its Interim Chief Executive Officer from 2007 to 2008. Dr. Gage currently serves on the board of directors of Marine Biological Laboratories. Dr. Gage received an S.B. in physics from the Massachusetts Institute of Technology and a Ph.D. in biophysics from the University of Chicago.

Garen Bohlin

Garen Bohlin has served as a member of our board of directors since July 2010. Since May 2012, Mr. Bohlin has served on the boards of directors and as a consultant to multiple life sciences companies. From January 2010 until April 2012, he served as Executive Vice President of Constellation Pharmaceuticals, Inc., a biopharmaceutical company. Prior to joining Constellation, Mr. Bohlin served as Chief Operating Officer of Sirtris Pharmaceuticals, Inc., a biotechnology company, from 2006 to December 2009. Mr. Bohlin was the founding Chief Executive Officer of Syntonix Pharmaceuticals, Inc., a biopharmaceutical company, from 1999 through December 2005. Earlier in his career, he held multiple executive positions at Genetics Institute, Inc., a biotechnology company, and was a partner at Arthur Andersen & Co., a public accounting and consulting organization. Mr. Bohlin currently serves on the board of directors of Collegium Pharmaceutical, Inc., Karyopharm Therapeutics, Inc. and Proteon Therapeutics, Inc., all publicly traded biotechnology companies. He also served on the board of directors for Acusphere, Inc., a specialty pharmaceutical company that was a publicly traded company, from 2005 to 2014, SpringLeaf Therapeutics, Inc., a private biotechnology company, from 2010 to 2013 and Precision Dermatology, Inc., a private dermatology company from 2012 to 2014. Mr. Bohlin received his B.S. in accounting and finance from The University of Illinois.

Independent Director

Chairman of the Finance and Audit Committee

Jeffrey A. Chodakewitz, M.D.

Jeffrey A. Chodakewitz, M.D. has served as a member of our board of directors since June 2014. Dr. Chodakewitz currently serves as a senior advisor to Blackstone Life Sciences, a life sciences fund. From April 2018 to March 2019, Dr. Chodakewitz served as Executive Vice President, Clinical Medicine and External Innovation of Vertex Pharmaceuticals Incorporated, a publicly traded pharmaceutical company. From October 2014 to March 2018, Dr. Chodakewitz served as Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer of Vertex. From January 2014 to October 2014, Dr. Chodakewitz served as Senior Vice President and Chief Medical Officer of Vertex. Prior to joining Vertex, Dr. Chodakewitz spent more than 20 years at Merck & Co., Inc., where he held a variety of roles including Vice President of Clinical Research— Infectious Diseases & Vaccines, Vice President of Clinical Pharmacology/Early Stage Development, Senior Vice President of Late Stage Development, and Senior Vice President of Global Scientific Strategy (Infectious Diseases, Respiratory/Immunology). Prior to his tenure at Merck, he served as the Director of the HIV Outpatient Clinic at the Veterans Administration Medical Center in West Haven, Connecticut, and held various academic positions at Yale University and New York University Schools of Medicine. Dr. Chodakewitz serves on the board of directors of resTORbio, Inc., a publicly traded biopharmaceutical company focused on age-related diseases. Dr. Chodakewitz is a Diplomate of the National Board of Medical Examiners, the American Board of Internal Medicine (both Internal Medicine and Infectious Diseases). He received a B.S. in Biochemistry from Yale University, cum laude, and an M.D. from the Yale University School of Medicine.

Independent Director

Member of the Compensation Committee

John G. Freund, M.D.

John Freund, M.D. has served as a member of our board of directors since October 2012. Dr. Freund founded Skyline Ventures, a venture capital firm, in 1997 and has served as a managing director at Skyline since its founding. He is also co-founder, director and chief executive officer of Arixa Pharmaceuticals, Inc., a privately held antibiotic company. Prior to founding Skyline, Dr. Freund served as managing director in the private equity group of Chancellor Capital Management, a private capital investment firm. In 1995, he co-founded Intuitive Surgical, Inc. a medical device company, and served on its board of directors until 2000. From 1988 to 1994, Dr. Freund served in various positions at Acuson Corporation, a maker of ultrasound equipment that is now part of Siemens, most recently as Executive Vice President. Prior to joining Acuson, Dr. Freund was a general partner of Morgan Stanley Venture Partners from 1987 to 1988. From 1982 to 1988, Dr. Freund was at Morgan Stanley & Co., an investment banking company, where he co-founded the Healthcare Group in the Corporate Finance Department in 1983. He has served on the board of directors of Collegium Pharmaceutical, Inc., a publicly traded biotechnology company, since 2014; Proteon Therapeutics, Inc., a publicly traded biotechnology company, since 2014; SI-BONE, Inc., a publicly traded medical device company, since 2012; and Sutro Biopharma, Inc., a publicly traded biotechnology company, since 2014. Dr. Freund also serves on the board of directors of six U.S. registered investment funds managed by Capital Research and Management.  Dr. Freund is a member of the Advisory Board for the Harvard Business School Healthcare Initiative. Dr. Freund received a B.A. in history from Harvard College, an M.D. from Harvard Medical School, and an M.B.A. from Harvard Business School.

Independent Director

Member of the Nominating and Governance Committee

Member of the Finance and Audit Committee

Gerri Henwood

Gerri Henwood has served as a member of our board of directors since April 2015. Since 2008, Ms. Henwood has served as President and Chief Executive Officer and a director of Recro Pharma, Inc., a publicly traded specialty pharmaceutical company developing acute care products, including non-opioid therapeutics for the treatment of acute pain. From 2006 to 2013, Ms. Henwood served as the President of Malvern Consulting Group, or MCG. She is the co-founder of Auxilium Pharmaceuticals, Inc. and served as its President, Chief Executive Officer and director from 1999 to 2006. Prior to founding Auxilium, in 1985, Ms. Henwood founded, and was President and Chief Executive Officer of, a publicly traded contract research organization, IBAH, Inc., which was acquired by Omnicare, Inc. Prior to founding IBAH, Inc., Ms. Henwood began her career with Smith Kline & French, now part of GlaxoSmithKline plc, in the pharmaceutical management program. She held many positions there, including the position of head of Regulatory and Medical Affairs for the U.S. business and the position of Group Director – Marketing in the International Pharmaceutical Division. Ms. Henwood holds a B.S. in Biology from Neumann University.

Independent Director

Member of the Compensation Committee

Guy Macdonald

Guy Macdonald has served as a member of our board of directors since January 2008, in addition to serving as our President and Chief Executive Officer from January 2008 to August 2019. From August 2003 until January 2008, Mr. Macdonald served as Executive Vice President, Operations of Idenix Pharmaceuticals, Inc., a biopharmaceutical company. Prior to joining Idenix, he served in various positions at Merck & Co., Inc., a pharmaceutical company, from 1981 to 2003, most recently serving as the Vice President for Anti-Infective and Hospital Products. Mr. Macdonald currently serves as chairman of the board of Scynexis, Inc., a publicly traded biotechnology company. Mr. Macdonald received an Honours Degree in biochemistry from Dundee University in Dundee, Scotland.

Nancy J. Wysenski

Nancy Wysenski has served as a member our board of directors since March 2014. From December 2009 through June 2012, Ms. Wysenski served as the Executive Vice President and Chief Commercial Officer of Vertex Pharmaceuticals Incorporated, a publicly traded pharmaceutical company. Prior to joining Vertex, Ms. Wysenski held the position of Chief Operating Officer of Endo Pharmaceuticals, a 1,200-person specialty pharmaceutical company, where she led sales, marketing, commercial operations, supply chain management, human resources and various business development initiatives. Prior to her time at Endo, Ms. Wysenski participated in the establishment of EMD Pharmaceuticals, Inc., where she held various leadership positions, including the role of President and Chief Executive Officer from 2001 to 2006 and Vice President of Commercial from 1999 to 2001. From 1984 to 1998, Ms. Wysenski held several sales-focused roles at major pharmaceutical companies, including Vice President of Field Sales for Astra Merck, Inc. Ms. Wysenski serves as a director of Alkermes plc, a publicly traded biopharmaceutical company, and Dova Pharmaceuticals, Inc., another publicly traded biopharmaceutical company. She is a founder of the Research Triangle Park Chapter of the Healthcare Businesswomen’s Association and served on the Nominating Committee and National Advisory Board of the Healthcare Businesswomen’s Association. Ms. Wysenski received a B.S.N. in Nursing from Kent State University and an M.B.A. from Baldwin-Wallace College.

To:

Please enter a valid email address.

From:

Please enter a valid email address.

Share information about Tetraphase

Cancel

Thank you!
Your email has been sent.

Thank you for your request.

Someone will contact you shortly.

OK